Cassava Sciences

SAVANASDAQ

Small-company neuroscience development around filamin A biology hypothesis

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-10-02. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-10-02 · archived: kept for reference, not maintained · where each field comes from

neuroscienceAlzheimer disease

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for SAVA yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Pre-revenue.

Upcoming catalysts

No upcoming catalyst for Cassava Sciences has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.

Pipeline

DrugIndicationPhaseExpected data
SimufilamAlzheimer diseasePhase 3StoppedStudy stopped — registry▼
SavaDxAlzheimer disease biomarker testingPreclinicalNot disclosed▼

Analysis

We have not yet written an analysis of Cassava Sciences that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade SAVA commission-free on Webullvia Webull · Affiliate

Comparable companies

Annovis BioBiogenProthena

Sponsored

Get premium SAVA analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Cassava Sciences has 6 Phase 2 or 3 studies on ClinicalTrials.gov: 3 completed, 3 stopped early.

3

Completed

3

Stopped early

0

Ongoing

Stopped early

  • NCT05575076Phase 3 · started 2022 · terminated

    Simufilam in alzheimer disease · n=1081

    Reason given: sponsor decision

  • NCT05352763Phase 2 · started 2022 · terminated

    simufilam in alzheimer's disease · n=90

    Reason given: Sponsor Decision

  • REFOCUS-ALZPhase 3 · started 2021 · terminated

    Simufilam in alzheimer disease · n=1125

    Reason given: Sponsor decision

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.